Published on
October 31, 2024
- 10:00 GMT
Algiax Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Trial of AP-325 in Chronic Neuropathic Pain
DüSSELDORF, GERMANY, October 31, 2024 /EINPresswire.com/ -- - Last patient out achieved - Topline data expected by end of November 2024 - AP-325 is a small molecule aimed at reducing neuropathic pain by activating GABAA Algiax Pharmaceuticals GmbH …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
